John H. Sampson was appointed Director of Labcorp Holdings Inc., effective February 9, 2026. As of November 14, 2026, Labcorp Holdings Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from February 9, 2026 to August 14, 2026, naming 1 appointment (Form 8-K, February 9, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Labcorp Holdings Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Labcorp Holdings Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-02-09 to 2026-08-14. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Labcorp Holdings Inc. files it.
Also on the record for Labcorp Holdings Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 7.52% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
Selling to them or working with them? See who runs Labcorp Holdings Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Labcorp Holdings Inc. and the records around it.
Companies that share a holder
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
- The Vanguard Group also filed stake reports on 2385 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Labcorp Holdings Inc.
Get an email when Labcorp Holdings Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Labcorp Holdings Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Labcorp Holdings Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Labcorp Holdings Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-14 | Reported | not named in the filing | 8-K, 2026-08-14 | ||
| 2026-02-09 | In | Director | 2026-02-09 | 8-K, 2026-02-09 |
Who leads Labcorp Holdings Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: John H. Sampson, appointed, effective 2026-02-09 (filed 2026-02-09).
New leaders reset buying decisions — get the Full Report on Labcorp Holdings Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Labcorp Holdings Inc., with the record behind each one.
Find candidates like Director at Labcorp Holdings Inc.Every change, in the filing's words
Reported
On August 11, 2026, Megan D. Bailey notified Labcorp Holdings Inc. (the "Company") of her decision to resign as Executive Vice President and President, Central Laboratories and International of the Company, effective September 4, 2026.
- Effective September 1, 2026, Brian J. Caveney, M.D., the current Executive Vice President and President, Early Development Research Laboratories and Chief Medical and Scientific Officer of the Company, will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, with responsibility for the Company's Early Development Research Laboratories and Central Laboratories businesses.
Appointed: John H. Sampson, Director, effective 2026-02-09
Labcorp Holdings Inc. (the "Company") today announced that on February 6, 2026, the Company's Board of Directors (the "Board") appointed John H. Sampson, M.D., Ph.D., as a member of the Board, effective February 9, 2026.
- In connection with Dr. Sampson's appointment, the Board has appointed Dr. Sampson to the Quality and Compliance Committee.
- Dr. Sampson will be entitled to receive compensation for his service on the Board consistent with the Company's director compensation program, as described in the Company's most recent proxy statement, filed with the Securities and Exchange Commission on April 4, 2025.
- Dr. Sampson serves as vice chancellor for health affairs and dean of the University of Colorado Anschutz School of Medicine at the CU Anschutz medical campus.
- Before joining the CU Anschutz School of Medicine, Dr. Sampson held senior leadership roles at Duke University Health System, where he served as senior vice president and led the Duke Health Integrated Practice.
- He is a practicing neurosurgeon, a member of the National Academy of Medicine, and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease.
Tools for this story
Each opens in a new tab, filled in for Labcorp Holdings Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
